{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-016797","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.686284+00:00","generated_at":"2026-06-05T23:04:56.302599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome Q4 2023 net product revenue $71.5M (+193% YoY); net loss $98.7M; pipeline milestones on track","bullets":["Total net product revenue $71.5M in Q4 2023 (+193% YoY); full year $204.9M (+309% YoY).","Auvelity net sales $49.0M in Q4 ($130.1M FY); Sunosi $22.5M Q4 ($74.8M FY, +67% YoY).","Net loss Q4 $98.7M ($2.08/share) vs $61.2M loss in Q4 2022; FY loss $239.2M ($5.27/share).","NDA submissions for AXS-07 (migraine) and AXS-14 (fibromyalgia) expected 1H 2024; SYMPHONY topline Q1 2024.","Cash $386.2M at Dec 31, 2023, up from $200.8M; sufficient to fund ops into cash flow positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-016797","json":"https://secwatch.observer/filing/0000950170-24-016797.json","markdown":"https://secwatch.observer/filing/0000950170-24-016797.md","text":"https://secwatch.observer/filing/0000950170-24-016797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/0000950170-24-016797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/axsm-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:04:56.302599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"661984cd8c92b5b102096558611a1335d5b6f79b","claim":"Axsome Therapeutics, Inc. reported the fourth quarter and full year of 2023 results: revenue $71.5 million, net income $(2.08) per share, EPS $(2.08) per share.","evidence_excerpt":"Total net product revenues were $71.5 million and $204.9 million for the fourth quarter and full year of 2023, representing year-over-year growth of 193% and 309%, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/0000950170-24-016797-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of 2023"},{"label":"Revenue","value":"$71.5 million"},{"label":"Net income","value":"$(2.08) per share"},{"label":"EPS","value":"$(2.08) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}